Sugi Predict

Sugi Predict / Compounds / SCHEMBL10307552

SCHEMBL10307552

SCHEMBL10307552

CCN(CC)CCCC(O)(c1ccccc1)c1ccc2c(c1)OCO2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.61
▸ CHRM2 P08172 1/20 0.46
▸ CHRM4 P08173 1/20 0.46
▸ CHRM5 P08912 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ BCL2 P10415 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ HPGD P15428 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ MAPT P10636 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ TRPM8 Q7Z2W7 3/20 0.40
▸ KIF11 P52732 1/20 0.40
▸ ADRB1 P08588 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ADRA2A P08913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10307559 0.82 SIGMAR1 (0.90) SIGMAR1CHRM2CHRM4CHRM5CHRM1
SCHEMBL10307553 0.81 HTR2A (0.41) SIGMAR1ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL10307558 0.79 SIGMAR1 (0.55) SIGMAR1CHRM2CHRM4CHRM5CHRM1
SCHEMBL10307563 0.75 CHRM4 (0.70) SIGMAR1CHRM2CHRM4CHRM5CHRM1
SCHEMBL14552358 0.69 SOAT1 (0.47) ALDH1A1HPGDSMN1; SMN2KDM4EMAPT
SCHEMBL10541336 0.68 HPGD (0.44) ALDH1A1HPGDSMN1; SMN2KDM4EMAPT
SCHEMBL9716801 0.67 SIGMAR1 (0.62) SIGMAR1CHRM2CHRM4CHRM5CHRM1
SCHEMBL11390745 0.66 SIGMAR1 (0.61) SIGMAR1CHRM2CHRM4CHRM5CHRM1
SCHEMBL10307551 0.66 SIGMAR1 (0.39) SIGMAR1CHRM2CHRM4CHRM1CHRM3
SCHEMBL9150315 0.66 CYP3A4 (0.44) ALDH1A1HPGDSMN1; SMN2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3763419-A1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Anji Pharma (US) LLC (US) 2021-01-13 — — EP disclosed
EP-2661266-B1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ANJI PHARMA (US) LLC (US) 2020-09-16 — — EP disclosed
US-10610500-B2 Chemosensory receptor ligand-based therapies ANJI PHARMA (US) LLC (US) 2020-04-07 — — US disclosed
US-20190038576-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2019-02-07 — — US disclosed
US-9962344-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2018-05-08 — — US disclosed
US-9962344-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2018-05-08 — — US disclosed
US-20170020829-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2017-01-26 — — US disclosed
US-20170020829-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2017-01-26 — — US disclosed
US-9463170-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2016-10-11 — — US disclosed
US-9463170-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2016-10-11 — — US disclosed
US-20150265555-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2015-09-24 — — US disclosed
US-20150265555-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2015-09-24 — — US disclosed
US-9050292-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2015-06-09 — — US disclosed
US-9050292-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2015-06-09 — — US disclosed
US-20140030332-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2014-01-30 — — US disclosed
US-20140030332-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2014-01-30 — — US disclosed
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — US disclosed
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 SIGMAR1 370/4885CHRM2 885/4885CHRM4 757/4885
US-10610500-B2 Chemosensory receptor ligand-based therapies TAS1R2, TAS2R1, GPR119 SIGMAR1 370/4885CHRM2 885/4885CHRM4 757/4885
US-20150265555-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 SIGMAR1 370/4885CHRM2 885/4885CHRM4 757/4885
US-20170020829-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 SIGMAR1 370/4885CHRM2 885/4885CHRM4 757/4885
US-20190038576-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 SIGMAR1 370/4885CHRM2 885/4885CHRM4 757/4885
US-20140030332-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 SIGMAR1 370/4885CHRM2 885/4885CHRM4 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.